中国组织工程研究 ›› 2016, Vol. 20 ›› Issue (8): 1095-1103.doi: 10.3969/j.issn.2095-4344.2016.08.005

• 材料生物相容性 material biocompatibility • 上一篇    下一篇

可塑性纳米-羟基磷灰石/聚β-羟基丁酸与戊酸酯-聚乙二醇-庆大霉素药物释放系统的生物相容性及安全性

汤善华,刘继春,章柏平,郑燕科,吕仁发   

  1. 解放军第一八四医院骨科,江西省鹰潭市 335000
  • 收稿日期:2016-01-02 出版日期:2016-02-19 发布日期:2016-02-19
  • 通讯作者: 刘继春,硕士,副主任医师,解放军第一八四医院骨科,江西省鹰潭市 335000
  • 作者简介:汤善华,男,1972年生,江西省鄱阳市人,2006年解放军第一军医大学毕业,硕士,副主任医师,研究方向为生物材料开发与应用。
  • 基金资助:

    解放军南京军区重点课题(08Z017)

Biocompatibility and security of the plastic nano-hydroxyapatite/poly(beta-hydroxybutyrate- co-beta-hydroxyvalerate)-polyethylene glycol- gentamicin drug delivery system

Tang Shan-hua, Liu Ji-chun, Zhang Bo-ping, Zheng Yan-ke, Lv Ren-fa
  

  1. Department of Orthopaedics, the 184th Hospital of PLA, Yingtan 335000, Jiangxi Province, China
  • Received:2016-01-02 Online:2016-02-19 Published:2016-02-19
  • Contact: Liu Ji-chun, Master, Associate chief physician, Department of Orthopaedics, the 184th Hospital of PLA, Yingtan 335000, Jiangxi Province, China
  • About author:Tang Shan-hua, Master, Associate chief physician, Department of Orthopaedics, the 184th Hospital of PLA, Yingtan 335000, Jiangxi Province, China
  • Supported by:

    the Key Project of Nanjing Military Region of PLA, No. 08Z017

摘要:

文章快速阅读:

 

文题释义:
释药系统:通过聚乳酸、聚乙醇酸、丙交酯和乙交酯共聚物和聚乙内酯等材料延缓药物的释放速率,降低药物进入机体的吸收速率,从而起到更佳治疗效果的释药系统。但药物从制剂中的释放速率受外界环境如pH值等的影响。
庆大霉素珠链释药系统:是由银丝连接的、内含庆大霉素的多聚甲基丙烯酸甲酯小珠组成,当内含庆大霉素的多聚甲基丙烯酸甲酯的珠链植入体内,每个珠子可释放出高浓度的庆大霉素,可在局部获得持续的较高药物浓度,同时保持较低的血药浓度,避免全身系统用药的不良反应及难进入缺乏血供病灶区的弊端。

 

背景:庆大霉素珠链释药系统应用于临床以来,其被认为是治疗骨髓炎的有效方法;但其存在不能降解、需二次手术取出,滋生病原菌等缺点,故可生物降解的释药系统成为当前热点。以纳米技术构建的羟基磷灰石/聚β-羟基丁酸与戊酸酯-聚乙二醇-庆大霉素局部药物缓释系统可能解决当前应用的困境。
目的:评价可塑性骨修复重建和释药材料纳米羟基磷灰石/聚β-羟基丁酸与戊酸酯-聚乙二醇-庆大霉素局部药物缓释系统植入动物体内后可能引发的急、慢性全身、局部组织、皮内刺激及其细胞毒性和溶血反应,为骨髓炎的治疗寻找一种新的材料。
方法:以具良好可塑性能纤维蛋白胶为微球支架,纳米羟基磷灰石为载药核心,外包裹生物相容性好且降解可调控的聚羟基丁酸酯-羟基戊酸酯共聚物及聚乙二醇,承载硫酸庆大霉素制成可塑性纳米羟基磷灰石/聚β-羟基丁酸与戊酸酯-聚乙二醇-庆大霉素释药系统。按照GB/T16886.1-1997医用植入材料评价标准和所推荐的生物学和动物试验,对其进行急性全身毒性试验、植入试验、亚急性及慢性全身毒性试验、溶血试验、细胞毒性试验、皮内刺激试验。
结果与结论:①可塑性纳米-羟基磷灰石/聚β-羟基丁酸与戊酸酯-聚乙二醇-庆大霉素药物释放系统无毒性,材料埋置动物体内后未引起明显血生化指标及肝肾功能变化,病理组织切片示材料周围的包裹组织,其炎性变化符合一般的炎症变化转归规律。②植入体内后材料发生降解并被骨组织取代。③材料浸提液与血液混溶的溶血率为1.2%,低于标准规定的5%。④材料与人体骨髓细胞体外培养见细胞形态良好,细胞增殖正常。⑤动物背部皮内注射材料浸提液后按标准刺激反应判为无刺激。⑥说明可塑性纳米-羟基磷灰石/聚β-羟基丁酸与戊酸酯-聚乙二醇-庆大霉素药物释放系统具有良好的生物相容性及生物安全性。 

 ORCID: 0000-0003-4909-1225(Tang Shan-hua)

关键词: 生物材料, 纳米材料, 纳米-羟基磷灰石, 聚β-羟基丁酸, 戊酸酯, 聚乙二醇, 庆大霉素, 药物释放系统, 生物相容性, 生物安全性

Abstract:

BACKGROUND: Gentamicin bead chain is an effective drug delivery system for treatment of osteomyelitis, but it cannot be degraded, need to be removed by second operation, and can breed pathogens. As a result, biodegradable drug delivery systems become a hotspot. Nano- hydroxyapatite/poly(β-hydroxybutyrate-co-β-hydroxyvalerate)-polyethylene glycol-gentamicin (nano-HA/PHBV-PEG-GM-DDS) is considered to be a good choice for the current predicament.
OBJECTIVE: To evaluate the acute or chronic toxic reactions of the whole body and local tissues, intracutaneous stimulation, cytotoxicity and hemolytic reactions after bone remodeling and implantation of nano-HA/PHBV-PEG-GM-DDS, thus providing a new kind of material for treating osteomyelitis.
METHODS: Plastic nano-HA/PHBV-PEG-GM-DDS was prepared using plastic fibrin glue as microsphere scaffold and nano-HA as the core carrier of GM that was coated with PHBV and PEG. The acute, subacute/chronic toxicity, implantation, hemolysis, cytotoxicity and intracutaneous stimulation tests were performed according to the evaluated criteria of medical implanted materials as well as biological and animal trials recommended in GB/T16886.1-1997.
RESULTS AND CONCLUSION: The plastic nano-HA/PHBV-PEG-GM-DDS was nontoxic and caused no apparent changes in liver and kidney function and serum biochemical indexes. Pathological examination showed that the implanted material was covered with tissues, and inflammation changes accorded with the general regularity of inflammatory outcomes. After implantation, the nano-HA/PHBV-PEG-GM-DDS was biodegraded and replaced by osseous tissues. The hemolytic rate of the material extract to the composite diffusion solution was 1.2%, which was below the standard criteria (5%). Human bone marrow cells cultured in vitro with the plastic nano-HA/PHBV-PEG-GM-DDS grew normally with good morphology. There was no stimulation reaction according to the criteria after the diffusion solution was subcutaneously injected into the back of the animal. These findings indicate that the plastic nano-HA/PHBV-PEG-GM-DDS for treating osteomyelitis possesses excellent biocompatibility and security.